Preliminary results on clinical and endocrine studies in the treatment of menorrhagia with danazol.
Preliminary results are presented on the effect of 400, 200 and 100 mg of daily danazol on measured menstrual blood loss, in women with menorrhagia. Both 400 and 200 mg daily effectively suppressed menstrual blood loss, 400 mg reducing menstrual blood loss from a pretreatment mean of 456 +/- 48 ml to 45  +/- 26 ml and 6 +/- 5 ml during the second and third months of treatment. Menstrual blood loss on 100 mg danazol was only minimally reduced. After two to three months on danazol, the pituitary showed ability to respond to gonadotrophin releasing hormone and to oestradiol benzoate. A lack of effect of danazol on most coagulation and fibrinolytic factors was demonstrated.
D001780:Blood Coagulation Tests; D002986:Clinical Trials as Topic; D003613:Danazol / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008595:Menorrhagia / Q000097:blood / Q000188:drug therapy*; D011245:Pregnadienes / Q000627:therapeutic use*
D011245:Pregnadienes; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003613:Danazol